Drug Profile


Alternative Names: Gly-Pro-Glu; Glypromate; GPE

Latest Information Update: 12 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuren Pharmaceuticals
  • Class Neuroprotectants; Oligopeptides; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mild cognitive impairment

Most Recent Events

  • 28 Aug 2006 Clinical data from a media release have been added to the pharmacokinetics section
  • 27 Apr 2006 Neuren Pharmaceuticals has completed a phase II trial in mild cognitive impairment in Australia and New Zealand
  • 06 Jun 2005 Glycine-proline-glutamate has received fast track status for mild cognitive impairment by the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top